According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...
Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk ...
Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...
The term best semaglutide for weight loss in 2026 reflects growing consumer interest in medically supervised GLP-1 weight loss programs. As demand for effective and regulated weight management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback